



## High Frequency and Prevalence of Community-Based Asymptomatic SARS-CoV-2 Infection

Journal:	<i>Emerging Infectious Diseases</i>
Manuscript ID	EID-20-4766
Manuscript Type:	Research Letter
Date Submitted by the Author:	03-Dec-2020
Complete List of Authors:	Allan-Blitz, Lao-Tzu; Brigham and Women's Hospital Department of Medicine, Division of Global Health Equity Turner, Isaac; Curative Inc, Hertlein, Fred; Curative Inc. Klausner, Jeffrey; University of California Los Angeles Jonathan and Karin Fielding School of Public Health
Keywords:	Asymptomatic Infection, SARS-CoV-2, Epidemiology
Abstract:	Approximately 20-40% of SARS-CoV-2 infection is asymptomatic; however, data are limited on drivers of such infection. Among over 730,000 SARS-CoV-2 test results in Los Angeles between August-October, 2020, we found heterogenous frequencies of asymptomatic infection among various sup-populations. Further research is needed to delineate drivers of asymptomatic SARS-CoV-2 infection.

SCHOLARONE™  
Manuscripts

# EMERGING INFECTIOUS DISEASES<sup>®</sup>

## Author Checklist

First author and manuscript title:

- Upload a completed Author Checklist with each submission to EID.
- Note that EID follows the policies and recommendations of the [ICMJE](#).

Proprietary Considerations and Requirements	
	Authors agree that if their manuscript is accepted for publication in <a href="#">Emerging Infectious Diseases</a> , it will upon publication be in the public domain and can be used without liability for copyright infringement.
	This manuscript (or one with substantially similar content written by the authors) has not been published previously.
	This article was published on a preprint service and is available at this URL:
	<b>Preprint Updates:</b> Authors agree to update the archived preprint with their article's Digital Object Identifier (DOI), a link to the version of the article published in EID, and a complete citation upon publication in EID.
	The corresponding author is the primary contact for reviewing the edited manuscript and galley proofs. Must provide full contact information (mailing address, email address, phone number) in the manuscript text.
	Financial support for this content is clearly disclosed in the manuscript.
	Any organization or person with a financial interest in the subject matter is disclosed in the manuscript.
	Authors have disclosed any conflicts of interest related to this article. EID accepts the <a href="#">ICMJE Conflict of Interest form</a> .
	This research has been approved by appropriate human or animal subjects research review boards, which are named in the manuscript. Refer to <a href="#">ICMJE's recommendations for Protection of Research Participants</a> .
	DNA and amino acid sequences have been submitted to an open access sequence database, such as GenBank, and accession numbers are used to refer to the sequences.
	Authors have included written permission from the publishers of any figures or tables previously published or adapted from published figures or tables.
	Authors have included written permission from persons identifiable in photographs, case descriptions, or pedigrees.
	Authors have included written permission from persons named in personal communications (oral or written) stating that they agree to be named and that the information cited is accurate.
Authorship and Acknowledgments	
	All authors and contributors meet the <a href="#">ICMJE criteria for those roles</a> , and all persons who made substantial contributions to this work but who did not fulfill the authorship criteria are named in the acknowledgments.
	Provided <a href="#">Open Researcher and Contributor ID (ORCID)</a> identifiers for submitting and corresponding authors. EID also encourages providing ORCIDs for all other authors.
	Obtained written permission has been from all persons listed as authors of this manuscript.
	Obtained written permission from all persons listed in the acknowledgments.
	Provided a two-sentence biography for the first author, or for both authors if there are only two, in the manuscript text.
Consent for Editing	
	All authors understand and agree that their manuscripts will be copyedited to conform to EID's style, word count limits, and requirements for formatting, references, figures, units of measure, and scientific nomenclature. Authors should consult the journal's <a href="#">Quick Guide to Article Information</a> and <a href="#">Author Resource Center</a> for guidance before submission.

**Additional notes or statements:** [Click here to enter text.](#)

Dear Editor of *Emerging Infectious Diseases*,

The following letter: "High Frequency and Prevalence of Community-Based Asymptomatic SARS-CoV-2 Infection," we are submitting for your review.

This study is important because of the ongoing SARS-CoV-2 pandemic and the uncertainty regarding the role that asymptomatic infection plays in continued transmission. Here we present data from a large community-based sample to provide some of the most precise prevalence estimates of asymptomatic SARS-CoV-2 infection to date. More than 42% of infections were asymptomatic, and without testing would have gone undiagnosed, likely perpetuating the spread of infection. We also identify other potential drivers of asymptomatic infection. Such results may provide the ground work for ongoing research which could facilitate more precise and targeted public health prevention efforts.

The manuscript has been seen and approved by all authors mentioned below, all of whom have contributed significantly to the work. The manuscript has not been previously published nor is it being considered for publication elsewhere. No other papers from the same study have been published or submitted. The corresponding author's contact information is below.

Disclosures: Dr. Allan-Blitz has served as a consultant for Curative Inc. Dr. Klausner has served as the medical director of Curative Inc. during the observation period. Isaac Turner and Fred Hertlein have served as employees of Curative Inc. during the observation period.

Acknowledgements: The authors would like to acknowledge Curative Inc. and the City of Los Angeles.

We prefer the table to be published in black and white.

We thank you for your consideration,

Sincerely,

Lao-Tzu Allan-Blitz

**Authors:** Lao-Tzu Allan-Blitz,<sup>1,2</sup> Isaac Turner,<sup>2</sup> Fred Hertlein,<sup>2</sup> Jeffrey D. Klausner<sup>2,3</sup>

1. Brigham and Women's Hospital, Boston, MA
2. Curative Inc. San Dimas, CA
3. Fielding School of Public Health, University of California, Los Angeles

**Corresponding Author Contact Information:**

Lao-Tzu Allan-Blitz, MD

Brigham and Women's Hospital  
75 Francis Street  
Boston, MA 02115, USA  
Email: [lallan-blitz@partners.org](mailto:lallan-blitz@partners.org), phone: (805) 896-5313

**Alternative Author Information:**

Jeffrey D. Klausner, MD  
Department of Medicine, Infectious Disease  
10833 Le Conte Ave  
Los Angeles, CA 90095, USA  
Email: [jdklausner@mednet.ucla.edu](mailto:jdklausner@mednet.ucla.edu), phone: (310) 557-2273

Peer Review

1 **High Frequency and Prevalence of Community-Based Asymptomatic SARS-CoV-2**  
2 **Infection**

3 Lao-Tzu Allan-Blitz,<sup>1,2</sup> Isaac Turner,<sup>2</sup> Fred Hertlein,<sup>2</sup> Jeffrey D. Klausner<sup>2,3</sup>

4

5 1. Brigham and Women's Hospital, Boston, MA

6 2. Curative Inc. San Dimas, CA

7 3. Fielding School of Public Health, University of California, Los Angeles

8

9 Disclosures: Dr. Allan-Blitz has served as a consultant for Curative Inc. Dr. Klausner  
10 has served as the medical director of Curative Inc. during the observation period. Isaac  
11 Turner and Fred Hertlein have served as employees of Curative Inc. during the  
12 observation period.

13

14 Acknowledgements: The authors would like to acknowledge Curative Inc. and the City  
15 of Los Angeles.

16

17 Author Biography: Lao-Tzu Allan-Blitz is a resident physician at Brigham and Women's  
18 Hospital in the Division of Global Health Equity.

19

20 Word Count: 734/800

21 Abstract Word Count: 49/50

22 References: 6/10

23 Tables: 1/1

24

25 **Corresponding Author Contact Information:**

26 Lao-Tzu Allan-Blitz

27 Department of Medicine, Brigham and Women's Hospital

28 75 Francis Street

29 Boston, MA 02115, USA

30 Email: [lao.allanblitz@gmail.com](mailto:lao.allanblitz@gmail.com), phone: (805) 896-5313

31

32 **Alternative Author Information:**

33 Dr. Jeffrey D. Klausner

34 Department of Epidemiology

35 Fielding School of Public Health

36 Los Angeles, CA 90095, USA

37 Email: [jdklausner@mednet.ucla.edu](mailto:jdklausner@mednet.ucla.edu)

38

39

40 **Abstract**

41 Approximately 20-40% of SARS-CoV-2 infection is asymptomatic; however, data are  
42 limited on drivers of such infection. Among over 730,000 SARS-CoV-2 test results in  
43 Los Angeles between August-October, 2020, we found heterogenous frequencies of  
44 asymptomatic infection among various sup-populations. Further research is needed to  
45 delineate drivers of asymptomatic SARS-CoV-2 infection.

46

Peer Review

## 47 **Background**

48           The economic impact of blanket closures in the wake of the SARS-CoV-2  
49 pandemic will be felt for years to come (1). Among other instances of infectious disease  
50 outbreaks, highly targeted interventions are feasible in part because we identify specific  
51 exposures that place individuals at increased risk for infection. If we are able to  
52 understand the exposures that drive the SARS-CoV-2 pandemic, we may be able to  
53 mitigate the economic impact by facilitating narrower public health interventions.

54           Of particular interest are the exposures that result in asymptomatic infection,  
55 which account for approximately 20-40% of infections (2) and contribute significantly to  
56 the continued transmission of SARS-CoV-2 (3). Some studies suggest that younger age  
57 and lack of other comorbidities may be particularly associated with asymptomatic  
58 SARS-CoV-2 infection, however more detailed data are lacking (4). Given that the  
59 spread of the SARS-CoV-2 pandemic appears to be heterogeneous (5), concentrating  
60 within specific hotspots of localized spread, developing a thorough understanding of the  
61 drivers of asymptomatic infection may be instrumental in the fight against the pandemic.  
62 We thus aimed to describe the frequency and prevalence of asymptomatic infection  
63 among a community-based sample in Los Angeles.

64

## 65 **Methods**

66           We evaluated SARS-CoV-2 RNA test results from a large testing program in Los  
67 Angeles between August-October 2020. Individuals presented to testing and were  
68 asked via a confidential online survey if in the last 14 days they had been contacted by  
69 local public health authorities about a known SARS-CoV-2 exposure, they visited any of



70 a list of public places, or they spent time with five or more strangers. We collected those  
71 data, as well as demographic data (age, gender, race, ethnicity, place of employment)  
72 and report of any symptoms from a pre-specified list. We then conducted a cross-  
73 sectional analysis to determine the frequency of infection among asymptomatic and  
74 symptomatic individuals.

75 The Mass General Brigham institutional review board deemed the analysis of de-  
76 identified data did not constitute human subjects' research (2020P003530).

77

## 78 Findings

79 We analyzed more than 730,000 test results (see Table), of which 54.4% were  
80 among women and 41.6% reported Hispanic or Spanish ethnicity. The mean age was  
81 34 years. The prevalence of SARS-CoV-2 infection among asymptomatic individuals  
82 was 4.2%. Among all who tested positive, 42.3% were asymptomatic. We found a  
83 higher prevalence of asymptomatic infection among individuals who reported work in  
84 construction and among racial and ethnic minorities. We also identified a higher  
85 prevalence of asymptomatic infection among individuals who had been contacted by a  
86 representative from a local health department regarding a known SARS-CoV-2  
87 exposure.

88

## 89 Discussion

90 We identified a high proportion of asymptomatic infection among those who  
91 tested positive for SARS-CoV-2. Additionally, the prevalence of infection among the  
92 asymptomatic fraction was high, providing support for screening of asymptomatic

93 individuals at risk for infection. The increased prevalence of infection (asymptomatic and  
94 symptomatic) among those who reported being contacted by a representative from a  
95 local health department about a known SARS-CoV-2 exposure provides strong  
96 evidence of the benefits of contact-notification in case-identification.

97         The different frequencies of asymptomatic infection among the different  
98 employment categories likely represent heterogeneity in risk of exposure. However,  
99 further research into particular exposures within different occupations may be of use in  
100 delineating the drivers of asymptomatic infection. Our data were limited in that we did  
101 not have more exposure data related to dining or social behaviors.

102         Thus, testing centers should strive to routinely collect data on potential  
103 exposures in the past 7 days. Data regarding specific venues of exposure (e.g. gyms,  
104 places of worship, parks, museums, hospitals, nursing homes, overnight camps, hotels,  
105 beaches, movie theaters, bars, restaurants, and airports) among individuals who test  
106 both positive and negative will enable more precise delineation of recent transmission  
107 events in real time. Such geographic information may function to enhance network  
108 mobility data to identify recent hotspots and venues where transmission mitigation  
109 efforts would be most helpful (6). More granular exposure data might enable public  
110 health officials to move from broad county and state lockdowns towards a more,  
111 targeted less harmful approach. The identification of particular high-risk activities or  
112 business practices might allow regulators like state occupational safety and health  
113 administrations to propose or enforce regulations to reduce the spread of infection.  
114 Given the relatively low prevalence of infection in certain areas there is ample  
115 opportunity to enhance prevention of SARS-CoV-2 spread through the use of exposure

116 data and strategic evidence-based interventions. In the meantime, continued screening  
117 of at-risk persons regardless of symptom status is warranted.

118

119

120

Peer Review

**121 References**

- 122 1. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic  
123 implications of the coronavirus pandemic (COVID-19): A review. *Int J Surg.* 2020;78:185-93.
- 124 2. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative  
125 Review. *Ann Intern Med.* 2020;173(5):362-7.
- 126 3. Nikolai LA, Meyer CG, Kreamsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2  
127 infection: Invisible yet invincible. *Int J Infect Dis.* 2020;100:112-6.
- 128 4. Gao A XY, Sun C, Wang X, Guo Y, Qiu S, Ma K. A systematic review of asymptomatic  
129 infections with COVID-19. *J Microbiol Immunol Infect.* 2020.
- 130 5. Britton T, Ball F, Trapman P. A mathematical model reveals the influence of population  
131 heterogeneity on herd immunity to SARS-CoV-2. *Science.* 2020;369(6505):846-9.
- 132 6. Chang S, Pierson E, Koh PW, Gerardin J, Redbird B, Grusky D, et al. Mobility network  
133 models of COVID-19 explain inequities and inform reopening. *Nature.* 2020.

134

135

136

137

138

139

140

141

142

143

144 **Table: Prevalence of SARS-CoV-2 Positivity Among Symptomatic and Asymptomatic**  
 145 **Individuals Presenting for Testing in Los Angeles, August - October 2020**

146

	Individuals Tested for SARS-CoV-2 (n=730,801)	
	Asymptomatic (n=402,918)	Symptomatic (n=289,052)
<b>Total</b>	4.2%	8.0%
<b>Age</b>		
<18 years (n=56,127)	9.5%	14.4%
18-24 years (n=115,608)	4.9%	8.8%
25-34 years (n=263,306)	2.8%	5.8%
35-49 years (n=180,729)	3.6%	7.8%
50-64 years (n=89,322)	4.7%	10.1%
≥ 65 years (n=25,709)	4.1%	9.3%
<b>Gender</b>		
Female (n=397,159)	3.9%	7.3%
Male (n=330,269)	4.6%	9.0%
Other (n=3,373)	1.6%	2.5%
<b>Race</b>		
American Indian or Alaska Native (n=3,936)	5.8%	10.3%
Black or African American (n=34,998)	2.2%	5.1%
Native Hawaiian or Other Pacific Island (n=5,200)	2.0%	5.0%
Prefer not to share (n=69,888)	6.1%	11.0%
Asian (n=82,480)	1.0%	2.5%
Multiracial (n=37,792)	1.8%	4.4%

	Other (n=192,255)	9.4%	14.9%
	White (n=304,252)	2.3%	4.8%
<b>Ethnicity</b>			
	Hispanic (n=304,185)	9.3%	13.8%
	Non-Hispanic (n=399,623)	1.4%	3.1%
<b>Month</b>			
	August (n=273,198)	5.7%	10.1%
	September (n=235,854)	3.5%	6.5%
	October (n=221,749)	3.3%	6.5%
<b>Employment*</b>			
	Construction Worker (n=529)	5.7%	10.1%
	Delivery, Transportation, Ride-Share (n=1,639)	2.3%	5.4%
	First Responder (n=12,043)	2.6%	7.4%
	Government Employee (n=716)	1.7%	7.4%
	Grocery Store Worker (n=8,387)	3.1%	7.5%
	Healthcare Personnel (n=56,174)	3.4%	6.4%
	Media Employee (584)	1.8%	4.9%
	Correctional Worker (n=131)	0.0%	12.5%
	Disability Care Provider (n=5,918)	1.6%	3.7%
	Education (n=3,771)	1.6%	4.8%
	Elderly Care (n=1,862)	2.9%	5.5%
	Food Services (n=53,372)	3.8%	7.8%
	Retail or Manufacturing (n=1,809)	2.5%	5.7%
	None of the Above (n=54,174)	3.0%	5.6%
<b>Notified About a Positive Contact in Last 14 days*†</b>			

	No (n=25,556)	2.1%	4.1%
	Yes (n=140,858)	9.6%	15.3%
<b>Visited Public Places in Last 14 Days*</b>			
	Yes (n=90,087)	0.9%	3.4%
<b>Spent time with <math>\geq 5</math> Strangers in Last 14 Days*</b>			
	Yes (n=3,765)	2.3%	6.4%

\* Data collection methods changed to include these questions as of September 15th 2020

† Contacted by local health department via contact-notification efforts

147

Peer Review